✨
AI Summary
- Psychedelic medicine dealmaking environment influenced by recent acquisitions.
- Eli Lilly's acquisition of AtaiBeckley and Compass Pathways' FDA filing.
- A more relaxed regulatory environment supports psychedelic therapy development.
Guests on This Episode
EW
Emma Wille
(born 1840) · 4 podcast appearances
JH
Joseph Haas
4 podcast appearances